A comprehensive view of Allorion Therapeutics. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Allorion Therapeutics announces exclusive option and global license agreement for novel preclinical-stage EGFR L858R allosteric inhibitor program with AstraZeneca
Published: January 03, 2024 by Canada Newswire
Allorion Therapeutics partners with AstraZeneca for global license agreement to develop new lung cancer treatment; AstraZeneca will license Allorion's L858R EGFR inhibitor, with Allorion set to receive up to US$540.0M in payments and worldwide royalties
Published: January 02, 2024 by Allorion Therapeutics

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count